Arms Sales Transparency: A Crack in the Facade?

The United States has been involved in one of its largest arms transfers to Israel under Donald Trump’s presidency, with a proposed sale of $2.8 billion worth of 40,000 bombs, including some of the most destructive conventional munitions in the US arsenal. However, this transfer has hit a roadblock due to objections raised by Gregory Meeks, the top Democrat on the House foreign affairs committee.

Meeks’ decision is not without precedent, but it highlights growing tension between Congress and the executive branch over arms sales transparency. The issue at hand is not just about the scale of the proposed transfer or its potential implications for regional security; rather, it’s a reflection of deeper concerns surrounding Israel’s use of American-made weapons.

The Leahy laws, which prohibit US assistance to foreign military units credibly linked to extrajudicial killings and serious abuse, have been invoked in this case. At least five Israeli units have been flagged by the state department for potential wrongdoing, including one battalion implicated in the death of a Palestinian American at a West Bank checkpoint. The Geneva conventions also come into play here, as they bar arming a party where there is a clear risk of war crimes.

The Biden administration’s handling of this situation has been somewhat ambiguous. While officials have publicly avoided making any determination about Israel’s use of American weapons in Gaza, internal memos suggest that some lawyers had concluded it was reasonable to assess that Israel had violated international humanitarian law and Leahy laws by using those same weapons.

Meeks’ objections are not aimed at the Israeli government per se; rather, they reflect Congress’s responsibility to ensure that US-funded weapons are used lawfully, responsibly, and with meaningful safeguards for human life. He has emphasized that this decision does not diminish congressional support for Israel’s legitimate defense needs.

The hold on the $2.8 billion arms sale serves as a stark reminder of the complex dynamics at play in international relations. Arms sales have long been a contentious issue, often reflecting broader geopolitical tensions and national security interests. In this case, Meeks’ decision to block the sale may be seen as a strategic move aimed at reasserting congressional oversight over the executive branch’s arms sales policies.

A similar instance of executive overreach occurred in 2025 when Marco Rubio declared a national security emergency to bypass congressional review and fast-track nearly $3 billion in weapons for Israel. This decision was seen as an attempt by the administration to circumvent oversight and expedite arms sales, raising concerns about accountability and transparency.

Congress’s role in this situation is complex, balancing competing national security interests with human rights concerns. Lawmakers must engage in a nuanced and informed discussion about the implications of these transfers, weighing the need for military aid against the risk of enabling war crimes.

As the debate over US-Israel relations continues to evolve, one thing is clear: Congress will play a pivotal role in shaping the trajectory of these policies and ensuring that American-made weapons are used responsibly and lawfully. The decision to hold up the $2.8 billion arms sale may be seen as a small crack in the facade of arms sales transparency, but it’s an important step forward nonetheless.

As lawmakers move forward, they must remain vigilant about the need for transparency and accountability in arms sales. This decision may be just the beginning of a new era of congressional oversight, one that prioritizes human rights concerns and ensures that US-funded weapons are used for the greater good – not just the interests of those with the loudest voices.